Van Bennekom CM, Kerr SM, Mitchell AA. Oseltamivir exposure in pregnancy and the risk of specific birth defects. Birth Defects Res. 2019 Aug 8
Influenza during pregnancy contributes to maternal morbidity and mortality. Neuraminidase inhibitors, including oseltamivir, are recommended for treating women with influenza during pregnancy.
Data from the Slone Birth Defects Study from 2009 to 2015 were used to investigate associations between oseltamivir and specific birth defects. We classified exposures according to timing in pregnancy and examined 52 and 16 defects with early and potential late pregnancy etiology, respectively; we calculated crude odds ratios (ORs) and 95% confidence intervals (CIs) for defects with three or more exposures.
Among 8,379 cases and 4,190 nonmalformed controls, we identified 79 and 42 oseltamivir exposures, respectively. The majority of defects had no exposures. ORs were elevated for several defects, but the CI excluded the null only for intestinal malrotation (OR: 10.7 [1.8, 45.2]; three exposures).
Largely null findings for specific defects are reassuring. The association with intestinal malrotation, while unstable, warrants further investigation.
- Identification of a pH Sensor in Influenza Hemagglutinin using X-ray Crystallography 1 days ago
- A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus 1 days ago
- Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents 1 days ago
- Aptamer Profiling of A549 Cells Infected with Low-Pathogenicity and High-Pathogenicity Influenza Viruses 1 days ago
- Changes in the Receptor-Binding Properties of H3N2 Viruses during Long-Term Circulation in Humans 1 days ago